Dublin, May 03, 2019 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

In recent years, there has been a steady increase in the interest shown in the cell therapy segment from big pharmaceutical, biotech and medical device companies. Earlier, the idea for altering a cell or a gene to cure or treat disease was considered impossible. But with the ongoing advancements, it has now become possible in the treatment or cure of a disease with the help of cell therapy.

Cell therapies are still in the early stages of clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell-based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that consideration will be given on how these therapies will be carried out and subsequently be delivered to the patients on a clinical relevancy scale.

Currently, there are more than 750 cell-based therapies in the clinical pipeline. Most of the cell therapies are in Preclinical phase followed by Phase-I clinical trials. Analysis of the pipeline shows that the majority of the cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer. More than 20 cell therapies are commercially available in the market. However, when it comes to marketed products, more than half of the products that are currently available are in the tissue and skin treatment segment such as Apligraf and Dermigraf.

The "Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights

• Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026
• Cell Therapy Clinical Trial Insight by Indication, Company & Country
• Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
• Globally Marketed Cell Therapies: 25 Cell Therapies
• Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
• Price & Product Insight By Region/Country
• Regional Analysis of the Cell Therapy Market

Companies Mentioned

• Athersys Inc.
• Baxter Healthcare Corporation
• Bloodworks
• Bone Therapeutics
• Celgene Corporation
• Cell Medica
• Cellerant Therapeutics
• Clinimmune Labs
• FibrocellScinence
• Genzyme Corporation
• Green Cross Cell
• Histogenics Corporation
• Intercytex
• Intrexon Corporation
• ISTO Biologics
• LifeSouth Community Blood Centers, Inc
• Macrocure
• MD Anderson Cord Blood Bank
• Mesoblast
• Molmed
• Nuo Therapeutics Inc
• OmniCyte
• Opexa Therapeutics
• Organogenesis
• Pharmicell
• Stem Cell Inc.
• TCA Cellular Therapy
• Teva Pharmaceuticals
• Tigenix & Vericel Corporation
• University of Colorado Cord Blood Bank
• Vericel Corporation

For more information about this report visit https://www.researchandmarkets.com/r/nlnrm7

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Clinical Trials